Mazdutide – 10mg

Mazdutide Peptide 10mg for Research Use

This product is not intended for weight loss, human consumption, or veterinary use. It is sold for research purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved.

Mazdutide (IBI362), a dual agonist targeting both GLP-1 and glucagon receptors, has shown promising results in clinical trials for weight management and metabolic disorders. This mazdutide peptide has been extensively studied in humans, but preclinical research, particularly in rat models, remains limited. Nonetheless, available studies provide valuable insights into its potential applications.

In a study involving hyperuricemic rats, mazdutide 10mg administration significantly reduced blood uric acid levels, outperforming and showing comparable efficacy to allopurinol, a standard treatment for hyperuricemia. Additionally, improvements in blood creatinine and urea nitrogen levels were observed, indicating potential benefits for kidney function (Innovent Biologics, 2023). These findings support ongoing interest in understanding optimal mazdutide peptide dosage profiles in controlled research settings.

Another study demonstrated that mazdutide administration in diabetic mice led to improved glucose control and reduced body weight, even in genetically modified mice lacking either GLP-1 or glucagon receptors. This suggests that mazdutide’s effects may be mediated through both receptor pathways (Ji et al., 2022).

Furthermore, mazdutide has been associated with reductions in liver fat content and improvements in insulin sensitivity in clinical trials, highlighting its potential for treating non-alcoholic fatty liver disease and type 2 diabetes (Innovent Biologics, 2023). With increasing research interest, laboratories exploring Mazdutide peptide for sale continue to expand the scientific understanding of its mechanisms and metabolic impact.

While these studies provide a foundation for understanding mazdutide’s effects in animal models, further research is necessary to fully elucidate its mechanisms and therapeutic potential. The combination of GLP-1 and glucagon receptor activation presents a novel approach to metabolic disease management, warranting continued investigation in preclinical and clinical settings.

References:

Innovent Biologics. (2023). Efficacy and safety of Mazdutide on weight loss among diabetic and overweight adults. PubMed Central. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911117/

Innovent Biologics. (2023). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) in Chinese adults with overweight or obesity. PubMed Central. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561728/

Ji, L., Gao, L., et al. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) in Chinese adults with overweight or obesity. EClinicalMedicine, 54, 101691. https://doi.org/10.1016/j.eclinm.2022.101691

Innovent Biologics. (2023). Innovent announces Phase 2 clinical study of higher dose 9 mg Mazdutide (IBI362) in Chinese adults with obesity achieved the 24-week primary endpoint. PR Newswire. https://www.prnewswire.com/news-releases/innovent-announces-phase-2-clinical-study-of-higher-dose-9-mg-mazdutide-ibi362-in-chinese-adults-with-obesity-achieved-the-24-week-primary-endpoint-301821038.html

Innovent Biologics. (2023). Innovent’s first new drug application of Mazdutide for chronic weight management has been accepted by the NMPA of China. BioSpace. https://www.biospace.com/innovent-s-first-new-drug-application-of-mazdutide-for-chronic-weight-management-has-been-accepted-by-the-nmpa-of-china